Neuren Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Neuren Pharmaceuticals şirketinin toplam hissedar öz sermayesi A$219.2M ve toplam borcu A$0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla A$228.2M ve A$9.0M dir. Neuren Pharmaceuticals 'in FAVÖK'ü A$155.2M faiz karşılama oranı -14.3 dur. Şirketin A$213.2M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

Borç/özkaynak oranı

AU$0

Borç

Faiz karşılama oranı	-14.3x
Nakit	AU$213.17m
Eşitlik	AU$219.15m
Toplam yükümlülükler	AU$9.00m
Toplam varlıklar	AU$228.15m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: NURP.F 'nin kısa vadeli varlıkları ( A$228.0M ) kısa vadeli yükümlülüklerini ( A$9.0M ) aşıyor.

Uzun Vadeli Yükümlülükler: NURP.F şirketinin kısa vadeli varlıkları ( A$228.0M ) uzun vadeli yükümlülüklerini ( A$29.0K ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: NURP.F borçsuzdur.

Borcun Azaltılması: NURP.F son 5 yıldır borcu bulunmamaktadır.

Borç Kapsamı: NURP.F un borcu yoktur, dolayısıyla işletme nakit akışı tarafından karşılanmasına gerek yoktur.

Faiz Kapsamı: NURP.F şirketinin borcu bulunmadığından faiz ödemelerinin karşılanması söz konusu değildir.

Neuren Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Neuren Phase 2 Trial Shows Significant Improvements in Pitt Hopkins Syndrome

Neuren Pharmaceuticals Limited, Annual General Meeting, May 28, 2024

Neuren Pharmaceuticals Limited to Report Q4, 2023 Results on Feb 29, 2024

Neuren Pharmaceuticals Limited Reiterates Net Sales Guidance for the Third Quarter of 2023

Neuren Pharmaceuticals Limited to Report First Half, 2023 Results on Aug 28, 2023

Neuren Pharmaceuticals Limited Announces Prader-Willi Syndrome IND for NNZ-2591 Approval by FDA

Neuren Pharmaceuticals Submits Investigational New Drug & First Patients Complete Phase 2 Trials

Neuren Pharmaceuticals Reports Rett Syndrome New Drug Application Accepted for Priority Review by US Food and Drug Administration

Neuren Pharmaceuticals Limited Commences Phase 2 Trials of NNZ-2591 in PMS and PTHS

Neuren Pharmaceuticals Limited Commences Phase 2 Trial of NNZ-2591 in Angelman

Neuren Pharmaceuticals Appoints Liza A. Squires as Chief Medical Officer in United States

Neuren Pharmaceuticals Limited Receives FDA Approval for Angelman IND and Phase 2 Trial

Neuren Pharmaceuticals Submits Investigational New Drug Application to the US Food and Drug Administration for NNZ-2591

Neuren Pharmaceuticals Limited announced that it expects to receive AUD 20.000001 million in funding

Neuren Pharmaceuticals Limited Submits an Investigational New Drug (IND) Application to the US Food and Drug Administration (FDA) for NNZ-2591 to Treat Angelman Syndrome

Neuren Pharmaceuticals Limited Receives Clear and Constructive Guidance from the Fda Office of Neuroscience in preIND Meetings for Phase 2 Clinical Trials of Nnz2591

Neuren Successfully Completes Drug Substance Manufacturing for NNZ-2591 Phase 2 Trials

Neuren Pharmaceuticals Limited Adds Prader-Willi Syndrome to Pipeline with Compelling Results for NNZ-2591 in Pre-Clinical Model

European Commission Grants 3 NNZ-2591 Orphan Designations to Neuren Pharmaceuticals

Neuren Pharmaceuticals Limited Receives Approval for Final Stage of NNZ-2591 Clinical Trial

Neuren Pharmaceuticals Limited Initiates Manufacture of Nnz-2591 for Phase 2 Trials

Neuren Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 0.215561 million.

Neuren Pharmaceuticals Limited announced that it has received AUD 20.000012 million in funding

Neuren Pharmaceuticals Limited announced that it expects to receive AUD 20 million in funding

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin